184 related articles for article (PubMed ID: 1663586)
21. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide.
Landmesser U; Drexler H
J Hypertens Suppl; 2006 Mar; 24(1):S39-43. PubMed ID: 16601572
[TBL] [Abstract][Full Text] [Related]
22. [Endothelial mechanisms in vasomotor effects of ACE inhibitors].
Busse R; Hecker M
Z Kardiol; 1994; 83 Suppl 4():1-6. PubMed ID: 7856274
[TBL] [Abstract][Full Text] [Related]
23. Glucose elevations alter bradykinin-stimulated intracellular calcium accumulation in cultured endothelial cells.
Pieper GM; Dondlinger L
Cardiovasc Res; 1997 Apr; 34(1):169-78. PubMed ID: 9217887
[TBL] [Abstract][Full Text] [Related]
24. Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide.
Ehring T; Baumgart D; Krajcar M; Hümmelgen M; Kompa S; Heusch G
Circulation; 1994 Sep; 90(3):1368-85. PubMed ID: 8087948
[TBL] [Abstract][Full Text] [Related]
25. ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts.
Linz W; Wiemer G; Schölkens BA
J Mol Cell Cardiol; 1992 Aug; 24(8):909-19. PubMed ID: 1331474
[TBL] [Abstract][Full Text] [Related]
26. Kinin B1 receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands.
Ignjatovic T; Stanisavljevic S; Brovkovych V; Skidgel RA; Erdös EG
Mol Pharmacol; 2004 Nov; 66(5):1310-6. PubMed ID: 15304551
[TBL] [Abstract][Full Text] [Related]
27. Modulation of agonist-induced calcium mobilisation in bovine aortic endothelial cells by phorbol myristate acetate and cyclic AMP but not cyclic GMP.
Buchan KW; Martin W
Br J Pharmacol; 1991 Oct; 104(2):361-6. PubMed ID: 1665733
[TBL] [Abstract][Full Text] [Related]
28. Effect of angiotensin-converting-enzyme inhibition on bradykinin metabolism by vascular endothelial cells.
Gräfe M; Bossaller C; Graf K; Auch-Schwelk W; Baumgarten CR; Hildebrandt A; Fleck E
Am J Physiol; 1993 May; 264(5 Pt 2):H1493-7. PubMed ID: 8388656
[TBL] [Abstract][Full Text] [Related]
29. Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin.
Marcic BM; Erdös EG
J Pharmacol Exp Ther; 2000 Aug; 294(2):605-12. PubMed ID: 10900238
[TBL] [Abstract][Full Text] [Related]
30. ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin.
Auch-Schwelk W; Bossaller C; Claus M; Graf K; Gräfe M; Fleck E
Cardiovasc Res; 1993 Feb; 27(2):312-7. PubMed ID: 8386065
[TBL] [Abstract][Full Text] [Related]
31. ACE inhibitor potentiation of bradykinin-induced venoconstriction.
Hecker M; Blaukat A; Bara AT; Müller-Esterl W; Busse R
Br J Pharmacol; 1997 Aug; 121(7):1475-81. PubMed ID: 9257930
[TBL] [Abstract][Full Text] [Related]
32. Stimulation of cyclic GMP production in cultured endothelial cells of the pig by bradykinin, adenosine diphosphate, calcium ionophore A23187 and nitric oxide.
Boulanger C; Schini VB; Moncada S; Vanhoutte PM
Br J Pharmacol; 1990 Sep; 101(1):152-6. PubMed ID: 2178013
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of bradykinin and resensitization of its B2 receptor.
Marcic B; Deddish PA; Jackman HL; Erdös EG
Hypertension; 1999 Mar; 33(3):835-43. PubMed ID: 10082496
[TBL] [Abstract][Full Text] [Related]
34. Bradykinin as a major endogenous regulator of endothelial function.
Gryglewski RJ; Uracz W; Chłopicki S; Marcinkiewicz E
Pediatr Pathol Mol Med; 2002; 21(3):279-90. PubMed ID: 12056503
[TBL] [Abstract][Full Text] [Related]
35. Calcium influx into endothelial cells and formation of endothelium-derived relaxing factor is controlled by the membrane potential.
Lückhoff A; Busse R
Pflugers Arch; 1990 May; 416(3):305-11. PubMed ID: 2381766
[TBL] [Abstract][Full Text] [Related]
36. Synergy of amlodipine and angiotensin-converting enzyme inhibitors in regulating myocardial oxygen consumption in normal canine and failing human hearts.
Mital S; Loke KE; Slater JP; Addonizio L; Gersony WM; Hintze TH
Am J Cardiol; 1999 Jun; 83(12A):92H-98H. PubMed ID: 10750596
[TBL] [Abstract][Full Text] [Related]
37. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.
Zhang X; Recchia FA; Bernstein R; Xu X; Nasjletti A; Hintze TH
J Pharmacol Exp Ther; 1999 Feb; 288(2):742-51. PubMed ID: 9918584
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of angiotensin-converting enzyme protects endothelial cell against hypoxia/reoxygenation injury.
Fujita N; Manabe H; Yoshida N; Matsumoto N; Ochiai J; Masui Y; Uemura M; Naito Y; Yoshikawa T
Biofactors; 2000; 11(4):257-66. PubMed ID: 11270506
[TBL] [Abstract][Full Text] [Related]
39. Endothelium-dependent effects of converting-enzyme inhibitors.
Vanhoutte PM; Boulanger CM; Illiano SC; Nagao T; Vidal M; Mombouli JV
J Cardiovasc Pharmacol; 1993; 22 Suppl 5():S10-6. PubMed ID: 7508046
[TBL] [Abstract][Full Text] [Related]
40. Activation of bradykinin B1 receptor by ACE inhibitors.
Ignjatovic T; Tan F; Brovkovych V; Skidgel RA; Erdös EG
Int Immunopharmacol; 2002 Dec; 2(13-14):1787-93. PubMed ID: 12489793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
